Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8<sup>+</sup> T cell immunity against bulky tumors via an IFN-I/NK/DC axis.

Nature communications·2026
Same author

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.

International journal of cancer·2026
Same author

Naïve pooling of randomized and non-randomized evidence in network meta-analyses: a meta-epidemiological study protocol.

Frontiers in medicine·2026
Same author

Clinical and Inflammatory Phenotypes During Exacerbations Predict In-Hospital Adverse Outcomes in Asthma-COPD Overlap.

Respirology (Carlton, Vic.)·2026
Same author

Physical fitness and bone health among medical students in Southwest China: implications for health promotion in ethnically diverse populations.

Journal of health, population, and nutrition·2026
Same author

Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.

International journal of cancer·2026

Related Experiment Video

Updated: Sep 20, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

201

Comparative effectiveness for early-stage NSCLC without lymph node involvement based on prospective studies.

Xue Yang1, Zherui Xing1, Sirui Long1

  • 1Division of Thoracic Tumor Multimodality Treatment, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

International Journal of Surgery (London, England)
|May 28, 2025
PubMed
Summary
This summary is machine-generated.

Systemic therapies like surgery plus adjuvant targeted therapy (ATKI) or stereotactic body radiation therapy (SBRT) with immunotherapy offer superior outcomes for early-stage non-small cell lung cancer (eNSCLC-N0). These advanced treatments improve disease-free survival (DFS) based on genomic status and patient tolerance.

Keywords:
early-stage NSCLCimmunotherapynetwork meta-analysispersonalized medicinestereotactic body radiation therapytargeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.7K

Related Experiment Videos

Last Updated: Sep 20, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

201
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.7K

Area of Science:

  • Oncology
  • Medical Research
  • Evidence Synthesis

Background:

  • Uncertainty exists in comparing surgical and nonsurgical treatments for early-stage non-small cell lung cancer (eNSCLC-N0).
  • Optimizing treatment strategies requires evaluating systemic therapies alongside local interventions.

Purpose of the Study:

  • To compare the efficacy of various treatment strategies for eNSCLC-N0.
  • To identify superior therapeutic approaches based on integrated evidence synthesis.

Main Methods:

  • Conducted an integrated evidence synthesis of randomized controlled trials (RCTs) and non-RCTs.
  • Utilized Bayesian random-effects network meta-analyses to evaluate treatment effects.
  • Primary outcomes included overall survival and disease-free survival (DFS).

Main Results:

  • Adjuvant targeted therapy (ATKI) significantly improved DFS compared to mixed radical resection.
  • For wild-type/unknown EGFR status, SBRT plus immune checkpoint inhibitors showed DFS benefit over SBRT alone.
  • SBRT plus immunotherapy was non-inferior to adjuvant platinum-based chemotherapy for DFS.

Conclusions:

  • Combination systemic therapies, including surgery plus ATKI or SBRT plus immunotherapy, are superior for eNSCLC-N0.
  • Treatment selection should consider genomic mutation status and patient tolerability.
  • These findings guide personalized treatment strategies for early-stage lung cancer.